All In Biotech

Investigational drug · Phase 3

LHRH Agonist

Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer, Early Breast Cancer, Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

6

6 still active

All registered trials

418

Any phase or sponsor naming "LHRH Agonist"

First trial start

2020

Oct 9, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "LHRH Agonist", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
  • Early Breast Cancer
  • Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
  • Locally Advanced or Metastatic Breast Cancer
  • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
  • Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Approved drugs for the same conditions: Breast cancer · Oncology · Endocrinology and women's health

Largest trials

Live from ClinicalTrials.gov: studies naming "LHRH Agonist" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 902 on PubMed

Also in development for Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

  • GiredestrantRO7197597, GDC-9545Phase 316 trials

    Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.